JP2024511160A - ヒト化ｍＡｂ１０７ - Google Patents

ヒト化ｍＡｂ１０７ Download PDF

Info

Publication number
JP2024511160A
JP2024511160A JP2023558760A JP2023558760A JP2024511160A JP 2024511160 A JP2024511160 A JP 2024511160A JP 2023558760 A JP2023558760 A JP 2023558760A JP 2023558760 A JP2023558760 A JP 2023558760A JP 2024511160 A JP2024511160 A JP 2024511160A
Authority
JP
Japan
Prior art keywords
antibody
seq
antigen
organ
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2023558760A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511160A5 (https=
Inventor
アルナウト，エム．，アミン
Original Assignee
ザ ジェネラル ホスピタル コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ジェネラル ホスピタル コーポレイション filed Critical ザ ジェネラル ホスピタル コーポレイション
Publication of JP2024511160A publication Critical patent/JP2024511160A/ja
Publication of JP2024511160A5 publication Critical patent/JP2024511160A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023558760A 2021-03-26 2022-03-25 ヒト化ｍＡｂ１０７ Withdrawn JP2024511160A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163166711P 2021-03-26 2021-03-26
US63/166,711 2021-03-26
PCT/US2022/021950 WO2022204516A1 (en) 2021-03-26 2022-03-25 Humanized mab107

Publications (2)

Publication Number Publication Date
JP2024511160A true JP2024511160A (ja) 2024-03-12
JP2024511160A5 JP2024511160A5 (https=) 2025-04-02

Family

ID=83397925

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023558760A Withdrawn JP2024511160A (ja) 2021-03-26 2022-03-25 ヒト化ｍＡｂ１０７

Country Status (7)

Country Link
US (1) US20240158511A1 (https=)
EP (1) EP4313112A4 (https=)
JP (1) JP2024511160A (https=)
CN (1) CN117355322A (https=)
AU (1) AU2022243562A1 (https=)
CA (1) CA3214962A1 (https=)
WO (1) WO2022204516A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026511370A (ja) * 2023-02-27 2026-04-14 カイジーン，インク． ヒト化抗ｃｄ１１ｂ抗体およびその使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2399148A1 (en) * 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
US10738121B2 (en) * 2015-02-27 2020-08-11 The General Hospital Corporation Therapeutic use of integrin-binding antibodies
CN107750255B (zh) * 2015-04-17 2022-08-30 安进研发（慕尼黑）股份有限公司 用于cdh3和cd3的双特异性抗体构建体
AU2016274175B2 (en) * 2015-06-12 2021-02-18 Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital Methods and polypeptides for modulation of immunoresponse

Also Published As

Publication number Publication date
AU2022243562A1 (en) 2023-10-12
US20240158511A1 (en) 2024-05-16
WO2022204516A1 (en) 2022-09-29
AU2022243562A9 (en) 2024-02-22
CN117355322A (zh) 2024-01-05
EP4313112A1 (en) 2024-02-07
EP4313112A4 (en) 2025-07-02
CA3214962A1 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
JP6860618B2 (ja) 抗補体Ｃ１ｓ抗体とそれらの用途
JP7427046B2 (ja) Ｂｄｎｆを含む融合蛋白質
JP7003348B2 (ja) 糖尿病黄斑浮腫の治療のための組成物および方法
US20230077885A1 (en) Methods for dna-dependent targeting of a cell permeant antibody
US20200231703A1 (en) Treatment of ocular disease
CN114929278A (zh) 抗ccr8抗体及其用途
TW202146445A (zh) 通過血腦障壁之抗人類運鐵蛋白受體抗體
TW201525001A (zh) 包含ｎ－端ａｂｐ之單鏈結合分子
JP2026053563A (ja) 補体関連疾患のための融合タンパク質構築物
KR20160147855A (ko) 항-인자 d 항체 변이체 및 이의 용도
US10927177B2 (en) Methods of treatment using anti-c-met antibodies
WO2022127834A1 (zh) 一种补体抑制剂的开发和应用
JP2024511160A (ja) ヒト化ｍＡｂ１０７
HK40112454A (zh) Lilrb2特异性单克隆抗体及其使用方法
CN118922443A (zh) 结合VEGF和Tie2的融合蛋白及其用途
NZ623275B2 (en) Treatment of ocular disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250325

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20251008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251008